drugset / Trial / NCT04305184

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

NCT04305184 ↗

Phase 1/2 Terminated 36 enrolled Astellas Pharma Global Development, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

The primary purpose of this study was to evaluate the safety and tolerability of ASP0598 Otic Solution. This study also evaluated the efficacy of ASP0598 otic solution.

Timeline

Start
2020-09-10
Primary completion
2023-01-24
Completion
2023-01-24

Outcome

Outcome not reported

Stopped: “Lack of Efficacy”

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP0598 Unknown 0.03 ug Other
Subject ASP0598 Unknown 0.15 ug Other
Subject ASP0598 Unknown 0.75 ug Other
Subject ASP0598 Unknown 2.25 ug Other

Indications